Marktanalyse - OTC Pharmaceuticals - Top 5 Emerging Markets Industry Guide

OTC Pharmaceuticals - Top 5 Emerging Markets Industry Guide is an essential resource for top-level data and analysis covering the OTC Pharmaceuticals industry in each of the Top 5 Emerging markets (Brazil, China, India, Mexico and South Africa). The report includes easily comparable data on market value, volume, segmentation and market share, plus full five year market forecasts. It examines future problems, innovations and potential growth areas within the market.

Scope of the Report

* Contains an executive summary and data on value, volume and segmentation

* Provides textual analysis of the industry's prospects, competitive landscape and profiles of the leading companies

* Incorporates in-depth five forces competitive environment analysis and scorecards

* Compares data from Brazil, China, India, Mexico and South Africa, alongside individual chapters on each country. .

* Includes a five-year forecast of the industry

Highlights

The top 5 emerging countries contributed $19,690.4 million to the global OTC pharmaceuticals industry in 2010, with a compound annual growth rate (CAGR) of 6.5% between 2007 and 2011.


The top 5 emerging countries are expected to reach a value of $26,137.8 million in 2015, with a CAGR of 5.8% over the 2010—15 period.


Within the OTC pharmaceuticals industry, China is the leading country among the top 5 emerging nations, with market revenues of $10,582.8 million in 2010.

The China is expected to lead the OTC pharmaceuticals industry in the top five emerging nations, with a value of $14,378.8 million in 2015.

Why you should buy this report

* Spot future trends and developments

* Inform your business decisions

* Add weight to presentations and marketing materials

* Save time carrying out entry-level research

Market Definition

The OTC pharmaceuticals market consists of the retail sale of traditional medicines, cough and cold preparations (tablets, mixtures, lozenges, topical remedies, inhalers), vitamins and minerals (multi-vitamins, single minerals, single vitamins, tonics, cod liver oil), indigestion preparations (tablets, powders, mixtures), analgesics (Paracetamol, Ibuprofen, Aspirinand other analgesics), and medicated skin products (anti-bacteria’s, acne treatments, anti-fungal, disinfectants and other), topical OTC medicines (anesthetic products, anti-itch products, antibiotic creams/gels), plasters & bandages (adhesive bandages/plasters, first aid tape, gauze pads/rolled gauze, liquid bandages and other tape or bandage), first aid kits and other (anti-smoking aids, rectal medications, eye/ear drops, sleeping aids, and motion sickness). The market is valued according to retail selling price (RSP) and includes any applicable taxes. Any currency conversions used in the creation of this report have been calculated using constant 2010 annual average exchange rates.

TABLE OF CONTENTS

Introduction 11

What is this report about? 11

Who is the target reader? 11

How to use this report 11

Definitions 11

Top 5 Emerging Countries OTC Pharmaceuticals Industy Outlook 12

OTC Pharmaceuticals in South Africa 15

Market Overview 15

Market Data 16

Market Segmentation 17

Market outlook 22

Five forces analysis 23

Leading companies 29

Macroeconomic indicators 34

OTC Pharmaceuticals in Brazil 36

Market Overview 36

Market Data 37

Market Segmentation 38

Market outlook 43

Five forces analysis 44

Leading companies 50

Macroeconomic indicators 60

OTC Pharmaceuticals in China 62

Market Overview 62

Market Data 63

Market Segmentation 64

Market outlook 69

Five forces analysis 70

Leading companies 76

Macroeconomic indicators 82

OTC Pharmaceuticals in India 84

Market Overview 84

Market Data 85

Market Segmentation 86

Market outlook 91

Five forces analysis 92

Leading companies 98

Macroeconomic indicators 109

OTC Pharmaceuticals in Mexico 111

Market Overview 111

Market Data 112

Market Segmentation 113

Market outlook 118

Five forces analysis 119

Leading companies 125

Macroeconomic indicators 137

Appendix 139

Methodology 139



LIST OF TABLES

Table 1:Top 5 emerging countries OTC pharmaceuticals industry, revenue ($m), 2006—15 12

Table 2:Top 5 emerging countries OTC pharmaceuticals industry, revenue ($m), 2006—10 13

Table 3:Top 5 emerging countries OTC pharmaceuticals industry forecast, revenue ($m), 2010—15 14

Table 4: South Africa OTC pharmaceuticals market value: $ million, 2006—10 16

Table 5: South Africa OTC pharmaceuticals market category segmentation: % share, by value, 2006—2010 17

Table 6: South Africa OTC pharmaceuticals market category segmentation: $ million, 2006-2010 17

Table 7: South Africa OTC pharmaceuticals market geography segmentation: $million, 2010 19

Table 8: South Africa OTC pharmaceuticals market share: % share, by value, 2010 20

Table 9: South Africa OTC pharmaceuticals market distribution: % share, by value, 2010 21

Table 10: South Africa OTC pharmaceuticals market value forecast: $ million, 2010—15 22

Table 11: Pharma Natura (Pty) Ltd: key facts 29

Table 12: Weleda Group: key facts 30

Table 13: GlaxoSmithKline Plc: key facts 31

Table 14: GlaxoSmithKline Plc: key financials ($) 32

Table 15: GlaxoSmithKline Plc: key financials (£) 32

Table 16: GlaxoSmithKline Plc: key financial ratios 32

Table 17: South Africa size of population (million), 2006—10 34

Table 18: South Africa gdp (constant 2000 prices, $ billion), 2006—10 34

Table 19: South Africa gdp (current prices, $ billion), 2006—10 34

Table 20: South Africa inflation, 2006—10 35

Table 21: South Africa consumer price index (absolute), 2006—10 35

Table 22: South Africa exchange rate, 2006—10 35

Table 23: Brazil OTC pharmaceuticals market value: $ million, 2006—10 37

Table 24: Brazil OTC pharmaceuticals market category segmentation: % share, by value, 2006—2010 38

Table 25: Brazil OTC pharmaceuticals market category segmentation: $ million, 2006-2010 38

Table 26: Brazil OTC pharmaceuticals market geography segmentation: $million, 2010 40

Table 27: Brazil OTC pharmaceuticals market share: % share, by value, 2010 41

Table 28: Brazil OTC pharmaceuticals market distribution: % share, by value, 2010 42

Table 29: Brazil OTC pharmaceuticals market value forecast: $ million, 2010—15 43

Table 30: Johnson & Johnson: key facts 50

Table 31: Johnson & Johnson: key financials ($) 51

Table 32: Johnson & Johnson: key financial ratios 52

Table 33: Sanofi-Aventis SA: key facts 54

Table 34: Sanofi-Aventis SA: key financials ($) 55

Table 35: Sanofi-Aventis SA: key financials (€) 55

Table 36: Sanofi-Aventis SA: key financial ratios 55

Table 37: Abbott Laboratories: key facts 57

Table 38: Abbott Laboratories: key financials ($) 58

Table 39: Abbott Laboratories: key financial ratios 58

Table 40: Brazil size of population (million), 2006—10 60

Table 41: Brazil gdp (constant 2000 prices, $ billion), 2006—10 60

Table 42: Brazil gdp (current prices, $ billion), 2006—10 60

Table 43: Brazil inflation, 2006—10 61

Table 44: Brazil consumer price index (absolute), 2006—10 61

Table 45: Brazil exchange rate, 2006—10 61

Table 46: China OTC pharmaceuticals market value: $ million, 2006—10 63

Table 47: China OTC pharmaceuticals market category segmentation: % share, by value, 2006—2010 64

Table 48: China OTC pharmaceuticals market category segmentation: $ million, 2006-2010 64

Table 49: China OTC pharmaceuticals market geography segmentation: $million, 2010 66

Table 50: China OTC pharmaceuticals market share: % share, by value, 2010 67

Table 51: China OTC pharmaceuticals market distribution: % share, by value, 2010 68

Table 52: China OTC pharmaceuticals market value forecast: $ million, 2010—15 69

Table 53: Johnson & Johnson: key facts 76

Table 54: Johnson & Johnson: key financials ($) 77

Table 55: Johnson & Johnson: key financial ratios 78

Table 56: Chengdu Rosun Antiseptic Pharmaceutical Co., Ltd.: key facts 80

Table 57: Huangshan Tianmu Pharmaceutical Co., Ltd.: key facts 81

Table 58: China size of population (million), 2006—10 82

Table 59: China gdp (constant 2000 prices, $ billion), 2006—10 82

Table 60: China gdp (current prices, $ billion), 2006—10 82

Table 61: China inflation, 2006—10 83

Table 62: China consumer price index (absolute), 2006—10 83

Table 63: China exchange rate, 2006—10 83

Table 64: India OTC pharmaceuticals market value: $ million, 2006—10 85

Table 65: India OTC pharmaceuticals market category segmentation: % share, by value, 2006—2010 86

Table 66: India OTC pharmaceuticals market category segmentation: $ million, 2006-2010 86

Table 67: India OTC pharmaceuticals market geography segmentation: $million, 2010 88

Table 68: India OTC pharmaceuticals market share: % share, by value, 2010 89

Table 69: India OTC pharmaceuticals market distribution: % share, by value, 2010 90

Table 70: India OTC pharmaceuticals market value forecast: $ million, 2010—15 91

Table 71: Cipla Ltd: key facts 98

Table 72: Cipla Ltd: key financials ($) 99

Table 73: Cipla Ltd: key financials (Rs.) 100

Table 74: Cipla Ltd: key financial ratios 100

Table 75: Johnson & Johnson: key facts 102

Table 76: Johnson & Johnson: key financials ($) 103

Table 77: Johnson & Johnson: key financial ratios 104

Table 78: GlaxoSmithKline Plc: key facts 106

Table 79: GlaxoSmithKline Plc: key financials ($) 107

Table 80: GlaxoSmithKline Plc: key financials (£) 107

Table 81: GlaxoSmithKline Plc: key financial ratios 107

Table 82: India size of population (million), 2006—10 109

Table 83: India gdp (constant 2000 prices, $ billion), 2006—10 109

Table 84: India gdp (current prices, $ billion), 2006—10 109

Table 85: India inflation, 2006—10 110

Table 86: India consumer price index (absolute), 2006—10 110

Table 87: India exchange rate, 2006—10 110

Table 88: Mexico OTC pharmaceuticals market value: $ million, 2006—10 112

Table 89: Mexico OTC pharmaceuticals market category segmentation: % share, by value, 2006—2010 113

Table 90: Mexico OTC pharmaceuticals market category segmentation: $ million, 2006-2010 113

Table 91: Mexico OTC pharmaceuticals market geography segmentation: $million, 2010 115

Table 92: Mexico OTC pharmaceuticals market share: % share, by value, 2010 116

Table 93: Mexico OTC pharmaceuticals market distribution: % share, by value, 2010 117

Table 94: Mexico OTC pharmaceuticals market value forecast: $ million, 2010—15 118

Table 95: Bayer AG: key facts 125

Table 96: Bayer AG: key financials ($) 126

Table 97: Bayer AG: key financials (€) 126

Table 98: Bayer AG: key financial ratios 127

Table 99: Johnson & Johnson: key facts 129

Table 100: Johnson & Johnson: key financials ($) 130

Table 101: Johnson & Johnson: key financial ratios 131

Table 102: Boehringer Ingelheim GmbH: key facts 133

Table 103: Boehringer Ingelheim GmbH: key financials ($) 134

Table 104: Boehringer Ingelheim GmbH: key financials (€) 134

Table 105: Boehringer Ingelheim GmbH: key financial ratios 135

Table 106: Mexico size of population (million), 2006—10 137

Table 107: Mexico gdp (constant 2000 prices, $ billion), 2006—10 137

Table 108: Mexico gdp (current prices, $ billion), 2006—10 137

Table 109: Mexico inflation, 2006—10 138

Table 110: Mexico consumer price index (absolute), 2006—10 138

Table 111: Mexico exchange rate, 2006—10 138



LIST OF FIGURES

Figure 1: Top 5 emerging countries OTC pharmaceuticals industry, revenue ($m), 2006—15 12

Figure 2: Top 5 emerging countries OTC pharmaceuticals industry, revenue ($m), 2006—10 13

Figure 3: Top 5 emerging countries OTC pharmaceuticals industry forecast, revenue ($m), 2010—15 14

Figure 4: South Africa OTC pharmaceuticals market value: $ million, 2006—10 16

Figure 5: South Africa OTC pharmaceuticals market category segmentation: $ million, 2006-2010 18

Figure 6: South Africa OTC pharmaceuticals market geography segmentation: % share, by value, 2010 19

Figure 7: South Africa OTC pharmaceuticals market share: % share, by value, 2010 20

Figure 8: South Africa OTC pharmaceuticals market distribution: % share, by value, 2010 21

Figure 9: South Africa OTC pharmaceuticals market value forecast: $ million, 2010—15 22

Figure 10: Forces driving competition in the OTC pharmaceuticals market in South Africa, 2010 23

Figure 11: Drivers of buyer power in the OTC pharmaceuticals market in South Africa, 2010 24

Figure 12: Drivers of supplier power in the OTC pharmaceuticals market in South Africa, 2010 25

Figure 13: Factors influencing the likelihood of new entrants in the OTC pharmaceuticals market in South Africa, 2010 26

Figure 14: Factors influencing the threat of substitutes in the OTC pharmaceuticals market in South Africa, 2010 27

Figure 15: Drivers of degree of rivalry in the OTC pharmaceuticals market in South Africa, 2010 28

Figure 16: GlaxoSmithKline Plc: revenues & profitability 33

Figure 17: GlaxoSmithKline Plc: assets & liabilities 33

Figure 18: Brazil OTC pharmaceuticals market value: $ million, 2006—10 37

Figure 19: Brazil OTC pharmaceuticals market category segmentation: $ million, 2006-2010 39

Figure 20: Brazil OTC pharmaceuticals market geography segmentation: % share, by value, 2010 40

Figure 21: Brazil OTC pharmaceuticals market share: % share, by value, 2010 41

Figure 22: Brazil OTC pharmaceuticals market distribution: % share, by value, 2010 42

Figure 23: Brazil OTC pharmaceuticals market value forecast: $ million, 2010—15 43

Figure 24: Forces driving competition in the OTC pharmaceuticals market in Brazil, 2010 44

Figure 25: Drivers of buyer power in the OTC pharmaceuticals market in Brazil, 2010 45

Figure 26: Drivers of supplier power in the OTC pharmaceuticals market in Brazil, 2010 46

Figure 27: Factors influencing the likelihood of new entrants in the OTC pharmaceuticals market in Brazil, 2010 47

Figure 28: Factors influencing the threat of substitutes in the OTC pharmaceuticals market in Brazil, 2010 48

Figure 29: Drivers of degree of rivalry in the OTC pharmaceuticals market in Brazil, 2010 49

Figure 30: Johnson & Johnson: revenues & profitability 52

Figure 31: Johnson & Johnson: assets & liabilities 53

Figure 32: Sanofi-Aventis SA: revenues & profitability 56

Figure 33: Sanofi-Aventis SA: assets & liabilities 56

Figure 34: Abbott Laboratories: revenues & profitability 59

Figure 35: Abbott Laboratories: assets & liabilities 59

Figure 36: China OTC pharmaceuticals market value: $ million, 2006—10 63

Figure 37: China OTC pharmaceuticals market category segmentation: $ million, 2006-2010 65

Figure 38: China OTC pharmaceuticals market geography segmentation: % share, by value, 2010 66

Figure 39: China OTC pharmaceuticals market share: % share, by value, 2010 67

Figure 40: China OTC pharmaceuticals market distribution: % share, by value, 2010 68

Figure 41: China OTC pharmaceuticals market value forecast: $ million, 2010—15 69

Figure 42: Forces driving competition in the OTC pharmaceuticals market in China, 2010 70

Figure 43: Drivers of buyer power in the OTC pharmaceuticals market in China, 2010 71

Figure 44: Drivers of supplier power in the OTC pharmaceuticals market in China, 2010 72

Figure 45: Factors influencing the likelihood of new entrants in the OTC pharmaceuticals market in China, 2010 73

Figure 46: Factors influencing the threat of substitutes in the OTC pharmaceuticals market in China, 2010 74

Figure 47: Drivers of degree of rivalry in the OTC pharmaceuticals market in China, 2010 75

Figure 48: Johnson & Johnson: revenues & profitability 78

Figure 49: Johnson & Johnson: assets & liabilities 79

Figure 50: India OTC pharmaceuticals market value: $ million, 2006—10 85

Figure 51: India OTC pharmaceuticals market category segmentation: $ million, 2006-2010 87

Figure 52: India OTC pharmaceuticals market geography segmentation: % share, by value, 2010 88

Figure 53: India OTC pharmaceuticals market share: % share, by value, 2010 89

Figure 54: India OTC pharmaceuticals market distribution: % share, by value, 2010 90

Figure 55: India OTC pharmaceuticals market value forecast: $ million, 2010—15 91

Figure 56: Forces driving competition in the OTC pharmaceuticals market in India, 2010 92

Figure 57: Drivers of buyer power in the OTC pharmaceuticals market in India, 2010 93

Figure 58: Drivers of supplier power in the OTC pharmaceuticals market in India, 2010 94

Figure 59: Factors influencing the likelihood of new entrants in the OTC pharmaceuticals market in India, 2010 95

Figure 60: Factors influencing the threat of substitutes in the OTC pharmaceuticals market in India, 2010 96

Figure 61: Drivers of degree of rivalry in the OTC pharmaceuticals market in India, 2010 97

Figure 62: Cipla Ltd: revenues & profitability 100

Figure 63: Cipla Ltd: assets & liabilities 101

Figure 64: Johnson & Johnson: revenues & profitability 104

Figure 65: Johnson & Johnson: assets & liabilities 105

Figure 66: GlaxoSmithKline Plc: revenues & profitability 108

Figure 67: GlaxoSmithKline Plc: assets & liabilities 108

Figure 68: Mexico OTC pharmaceuticals market value: $ million, 2006—10 112

Figure 69: Mexico OTC pharmaceuticals market category segmentation: $ million, 2006-2010 114

Figure 70: Mexico OTC pharmaceuticals market geography segmentation: % share, by value, 2010 115

Figure 71: Mexico OTC pharmaceuticals market share: % share, by value, 2010 116

Figure 72: Mexico OTC pharmaceuticals market distribution: % share, by value, 2010 117

Figure 73: Mexico OTC pharmaceuticals market value forecast: $ million, 2010—15 118

Figure 74: Forces driving competition in the OTC pharmaceuticals market in Mexico, 2010 119

Figure 75: Drivers of buyer power in the OTC pharmaceuticals market in Mexico, 2010 120

Figure 76: Drivers of supplier power in the OTC pharmaceuticals market in Mexico, 2010 121

Figure 77: Factors influencing the likelihood of new entrants in the OTC pharmaceuticals market in Mexico, 2010 122

Figure 78: Factors influencing the threat of substitutes in the OTC pharmaceuticals market in Mexico, 2010 123

Figure 79: Drivers of degree of rivalry in the OTC pharmaceuticals market in Mexico, 2010 124

Figure 80: Bayer AG: revenues & profitability 127

Figure 81: Bayer AG: assets & liabilities 128

Figure 82: Johnson & Johnson: revenues & profitability 131

Figure 83: Johnson & Johnson: assets & liabilities 132

Figure 84: Boehringer Ingelheim GmbH: revenues & profitability 135

Figure 85: Boehringer Ingelheim GmbH: assets & liabilities 136

• OTC Triptans in Azerbaijan
• Calming and Sleeping in Australia
• Calming and Sleeping in Croatia
• Cough, Cold and Allergy (Hay Fever) Remedies in Australia
• Cough, Cold and Allergy (Hay Fever) Remedies in Croatia
• Over-the-counter Pharmaceuticals Market in the Asia Pacific Region 2012-2016
• Over-the-counter Pharmaceuticals Market in the Asia Pacific Region 2012-2016
• Global Over-the-counter Pharmaceutical Market 2012-2016
• OTC Pharmaceuticals and Self-medication in Seven Emerging Markets
• OTC Triptans in Germany
• OTC Triptans in Sweden
• OTC Triptans in the United Kingdom
• Cough, Cold and Allergy (Hay Fever) Remedies in the US
• Rx-to-OTC Switching Strategies - New Switching Opportunities in Weight Management and Smoking Cessation, but Encouraging the Uptake of Self-Medication Remains a Challenge
• Global OTC Pharmaceuticals
• OTC Pharmaceuticals - BRIC (Brazil, Russia, India, China) Industry Guide
• OTC Pharmaceuticals - Global Group of Eight (G8) Industry Guide
• OTC Pharmaceuticals - North America (NAFTA) Industry Guide
• OTC Pharmaceuticals - Scandinavia Industry Guide
• OTC Pharmaceuticals in Asia-Pacific